Biotechnology firm focused on cancer therapeutic development,, has received a United States patent grant for the company’s anti-cancer compound, VAL201.
This morning’s announcement follows ValiRx’s earlier statement on 26 June 2019 which saw the US Patent and Trademark Office allow patent claims for the use of VAL201 in the prevention and treatment of metastatic (including prostate) cancer.
The VAL201 compound is currently undergoing clinical trials for the treatment of prostate cancer and potentially other indications of hormone induced unregulated growth including endometriosis.
The grant, covering one of ValiRx’s largest commercial markets, will provide patent protection to regulate symptoms of metastatic cancer which occurs when the disease spreads from its site of origin to other parts of the body.
Shares in ValiRx were trading 3.85% higher at 0.135p during Thursday morning.
The patent works to prevent the worsening of symptoms, reduce progression and even treat this type or underlying cancer via administration of the VAL201 peptide.
VL201 prevents tumour growth “selectively” by inhibiting the proliferation of tumour cells, the company explained.
The compound’s clinical trials have so far “met its endpoints very well” allowing ValiRx to use the peptide to demonstrate VL201 as a therapeutic product in what is considered “a poorly-served, yet very substantial commercial market.”
Dr Satu Vainikka, CEO of ValiRx said that the US patent grant represents “a key addition” to the group’s patent coverage and protection for this indication.
Dr Vainikka further demonstrated the validation of ValiRx’s potential anti-cancer impact under the basis that all primary cancers have the ability to metastasise and spread to other parts of the body at any point.
Follow News & Updates from ValiRx here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Xpediator discuss the highs and lows from 2019 and what's to come in 2020. Cora Gold discuss their maiden resource at Sanankoro and also provides an update on Hummingbird Resources. Russ Mould talks about the Saudi Aramco IPO & OPEC's latest meeting.
“We are delighted to welcome Ged Hall to the Board at such an exciting time as we look to progress the Mahenge Liandu graphite project from exploration to production,” said Johansen.
ReNeuron said it was in ongoing discussions with other commercial third parties for potential out-licence deals and Chief Executive, Olav Hellebø, says he expects to announce further deals “in the months ahead.”
Lawrence Stroll, the billionaire owner of the Racing Point Formula One motor racing team, is said to be preparing to bid for a significant stake in Aston Martin, BP has increased its stake in the British solar venture Lightsource BP as it prepares to strike a deal to power its offices with renewable energy from next year
O2 announced the launch of O2 extras this morning to offer flexibility and affordability for its customers -- the programme will be on offer to new and upgrading pay monthly customers on a handset, tablet or SIM only contracts.
Nuformix (NFX) Chief Executive Officer Dr. Dan Gooding discusses some of the speculation surrounding the leaked article in the press, answers questions investors had regarding upcoming licensing deals, and discusses a potential exit strategy for the company.